Pfizer portfolio to expand with integration of Alpharma
Integration next step after recent acquisition of King Pharmaceuticals
With the acquisition of King Pharmaceuticals by Pfizer Inc. announced on Feb. 28, Pfizer Animal Health will begin integrating Alpharma LLC into its existing business, resulting in a more diversified portfolio of products and services.
Alpharma was a wholly owned subsidiary of King Pharmaceuticals and became part of Pfizer Animal Health with Pfizer’s acquisition of King. The integration of Alpharma allows Pfizer Animal Health to build on its portfolio of biologics, medicines and immunodiagnostics with Alpharma’s medicated feed additives and water-soluble therapeutics for the prevention and treatment of diseases. “Pfizer Animal Health welcomes Alpharma colleagues and the company’s respected products and services,” said Clint Lewis, president of U.S. operations for Pfizer Animal Health. “[This integration] marks another important milestone in Pfizer Animal Health’s evolution in offering veterinarians, nutritionists and all our customers a more comprehensive portfolio of unique products and services."